Compare Abeona Therapeutics Inc (ABEO) vs Zoetis Inc (ZTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Zoetis Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Zoetis Inc trades at $75.69 (market cap $31.62B). The key difference: Zoetis Inc is far larger — about 84.7× Abeona Therapeutics Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ZTS | |
|---|---|---|
Market Cap | $373.32M | $31.62B |
Sector | Health | Health |
52-Week High | $7.23 | $158.80 |
52-Week Low | $4.17 | $71.91 |
Enterprise Value | $228.22M | $38.92B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Zoetis (ZTS) trades at $76.29, up 1.99% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple class-action lawsuits filed against the company, creating investor uncertainty despite a consensus analyst price target of $101.43.
The stock presents a valuation opportunity with a P/E of 12.36 below industry averages, but faces near-term headwinds from legal challenges and mixed earnings performance. Upside potential exists if the company can overcome litigation concerns and return to consistent earnings beats, while downside risk persists from ongoing legal proceedings and competitive pressures in the animal health market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
